Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy
This article was originally published in PharmAsia News
Takeda is discontinuing development of a Phase II compound, TAK-128, for the treatment of peripheral diabetic neuropathy after the candidate failed to show sufficient efficacy to support its continued development, the company reported
You may also be interested in...
Compound fails to measure up to exisiting treatments, firm says.
Takeda will consider terminating its licensing and development agreement for the investigational drug.
Takeda's existing Actos sales force will detail the pioglitazone and glimepiride combination therapy to primary care physicians.